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for the lmazodan Research Group* 
A 12=week, multicenter, double-blind, random- 
ized, placebo-controlled trial of imazodan, a type 
Ill phosphodiisterase inhibitor, was conducted in 
147 patients with congestive heart failure to de- 
termine clinical efficacy and safety. Patients 
were randomized to placebo or 2,s or 10 mg of 
imazodan administered twice daily. Patients 
were maintained on their standard therapy in- 
cluding diuretics, digoxin and an angiotensin- 
converting enzyme inhibitor. The mean ejection 
fraction was 23 f 10%. Exercise time increased 
from baseline in all 4 groups. There was no sig- 
nificant difference observed between the placebo 
group and any of the treated groups with regard 
to exercise time, ejection fraction, frequency of 
ventrieutar premature complexes or ventricular 
tachycardia. When analyzed by intent to treat, 
the placebo mortality was 7% (3 of 44) and the 
imazodan mortality was 8% (8 of 103) (p = not 
signifieant). This study failed to demonstrate 
that imazodan provided any benefit in exercise 
performance when compared with placebo. 
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T 
he optimal treatment of congestive heart failure 
(CHF) remains a major clinical issue despite 
treatment with digitalis and diuretics. The use 
of vasodilators,’ especially the angiotensin-converting 
enzyme inhibitors, 2,3 have improved both symptoms 
and prognosis. Nevertheless, the mortality of patients 
with advanced CHF remains high and many patients 
continue to be severely symptomatic despite medical 
therapy. Type III phosphodiesterase inhibitors may 
provide an alternative or additional treatment for CHF. 
These agents have demonstrated hemodynamic efficacy 
in the acute setting. 4-10 However, long-term trials 
studying the effect on exercise performance have gener- 
ally been disappointing.’ l-l6 
Imazodan hydrochloride (CI 9 14), a selective inhib- 
itor of type III phosphodiesterase, blocks the degrada- 
tion of cyclic adenosine monophosphate leading to in- 
creased intracellular concentrations, thereby increasing 
myocardial contractility. Imazodan also acts as a pe- 
ripheral vasodilator in a variety of animal models.i7 Ini- 
tial human studies8 indicated that after intravenous or 
oral administration of imazodan, cardiac output in- 
creases and pulmonary capillary pressure and systemic 
vascular resistance decrease. Pharmacokinetic studies 
suggested a half-life of 15 to 25 hours, allowing twice- 
daily administration. 
The primary objective of this study was to deter- 
mine whether, during a 12-week period, 1 or more dos- 
ing regimens of orally administered imazodan were 
more effective than placebo at increasing exercise time 
on a treadmill in patients with moderate to severe 
chronic CHF. 
METHODS 
Patient population: The study was designed to enroll 
160 patients. Recruitment was discontinued after 147 
patients were randomized after an analysis of the initial 
80 patients indicated that a positive effect of the drug 
was unlikely to be achieved. Each patient was required 
to provide written informed consent, be aged > 18 and 
<75 years and have chronic CHF in which dyspnea or 
fatigue limited their exercise. Patients were allowed to 
continue receiving antiarrhythmic agents except for di- 
sopyramide. Short-acting nitrates and constant doses of 
digitalis and angiotensin-converting enzyme inhibitors 
were permitted. Diuretic doses could be decreased, but 
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TABLE I Baseline Characteristics of Patient Population 
No. of Pts. 
(n = 147) 
Placebo 
(n = 44) 
lmazodan 
2 mg BID 
(n = 34) 
lmazodan 
5 mg BID 
(n = 37) 
lmazodan 
10 mg BID 
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35 (24) 12 (27) 
18 (12) 5 (11) 
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23 (68) 20 (54) 15 (47) 
0 (0) 5 (14) 4 (13) 
7 (21) 10 (27) 6 (19) 
4 (12) 2 (3) 7 (22) 
526 -f 128 462 2 160 502 k 127 
22 2 7 20 * 9 252 11 
0.18 
0.18 
140 Z!I 228 0.52 
85 r 12 0.36 
0.5 + 0.9 0.19 
27 (84) 0.83 
87 f 65 0.86 
20 (59) 20 (54) 16 (50) 0.90 
ACE = angiotensin-converting enzyme inhibitors; BID = twice daily: CAD = coronary artery disease; HR = heart rate; IDC = idiopathic dilated cardiomyopathy: NYHA = New York 
Heart Association; Other = valvular disease (51, congenital heart disease (3), heart disease not specified (10); SH = systemic hypertension; VPCs = ventricular premature complexes; 
V runs = ventricular runs > 4 beats at a rate > 100 beats/min. 
not increased from that taken during the placebo base- 
line phase. Women with child-bearing potential were 
excluded. 
Study design: This study was a double-blind, paral- 
lel-group comparison of imazodan therapy (2, 5 and 10 
mg, administered twice daily) with placebo in patients 
with chronic CHF. The study began with a 2- to 4- 
week, single-blind, placebo phase during which routine 
laboratory and cardiac studies were performed. 
During the baseline phase, treadmill exercise tests 
were performed each week using the Naughton proto- 
col modified by Weber et al.‘* Before randomization, 2 
consecutive symptom-limited maximal exercise toler- 
ance tests had to be performed between 4 and 12 min- 
utes and had to be reproducible to within 10%. Patients 
were then randomly assigned to 1 of the 4 treatment 
groups and were evaluated every week for 12 weeks. 
Exercise tests were performed at baseline and at weeks 
4, 8 and 12. Ejection fraction was measured by gated 
radionuclide angiography at baseline and 12 weeks. 
Twenty-four-hour Holter monitorings were performed 
at baseline and weeks 1, 4 and 10, and were analyzed 
at a central site (Cardiodata Inc.). Each tape was ana- 
lyzed for average 24-hour heart rate, ventricular pre- 
mature complexes per hour and ventricular runs (>4 
beats at a rate >I00 beats/min/day). 
Patients who withdrew from the study because of 
lack of efficacy before completing the 12 weeks were 
eligible to enter an open-label treatment program in 
which imazodan could be initiated or increased for 
symptomatic relief of CHF. 
Differences in baseline variables between treatment 
groups were analyzed by chi-square analysis for discon- 
tinuous variable and analysis of variance. Changes in 
exercise times, ejection fraction, 24-hour heart rate, fre- 
quency of ventricular premature complexes and ventric- 
ular runs were analyzed by 1 factor analysis of variance 
using treatment group as the independent factor. A p 
value <0.05 was considered significant. Definitions 
from the Cardiac Arrhythmia Pilot Study19 were used 
for determining proarrhythmia. 
Results were analyzed by intent to treat and also by 
end point analysis of the last laboratory determinant 
before the time the double-blind phase was broken be- 
cause of increased symptoms or death. For the double- 
blind phase and through 84 days, the relation of the 
treatment group to survival was examined by estimat- 
ing survival curves for each treatment using the prod- 
uct-limit method of Kaplan and Meier. The equality of 
the 4 survival distributions was tested by the log rank 
(Mantel-Cox) statistic. 
Data collection was performed by Parke-Davis 
Pharmaceutical Research Division. Data were analyzed 
at the Division of Cardiology, Henry Ford Heart and 
Vascular Institute with the assistance of the Depart- 
ment of Biostatistics, Henry Ford Hospital. 
A safety committee (see Appendix), established be- 
fore the study initiation, was charged with reviewing 
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the safety data. The members of the committee were 
unaware of patient characteristics and had access to the 
dose of drug each patient was receiving, description of 
deaths and other adverse events, 24-hour Holter moni- 
tor results and clinical laboratory findings. 
RESULTS 
The baseline characteristics of the 147 patients who 
entered the study are listed in Table I. The treatment 
groups were similar with respect to all baseline demo- 
graphic variables (Table I). 
Exercise response: Increases in exercise tolerance 
were seen in all groups compared with baseline (Figure 
1). There was no significant difference between the 4 
treatment groups in the change in exercise time from 
baseline to weeks 4, 8 and 12 (Table II). There was no 
significant change in ejection fraction between the 
treatment groups during the study period (Table III). 
Of the 146 patients who were classified by New 
York Heart Association class during both baseline and 
double-blind phases, 122 (84%) remained in the same 
class, 12 patients (8%) improved, and 12 were worse. 
There was no significant difference in class change be- 
tween the 4 treatment groups (p = 0.7). 
Arrhythmias: In the imazodan 5- and lo-mg 
groups, a significant increase in 24-hour average heart 
rates was observed at 1, 4 and 10 weeks (Table IV). 
No significant change occurred in the average fre- 
quency of ventricular premature beats per hour (Table 
V) or runs of ventricular ectopic beats compared with 
baseline in any treatment group at 1, 4 or 10 weeks. 
According to the Cardiac Arrhythmia Pilot Studylg 
definitions there were 15 patients who had proarrhyth- 
TABLE II Change in Exercise Time (seconds) from Baseline 
Visit lmazodan lmazodan lmazodan p 
(week) Placebo (2 mg BID) (5 mg BID) (10 mg BID) Value 
4 24 r 108 83 -t 79 75 f 121 32 f 123 0.08 
8 45-r-114 65~103 67k1.27 O-+ 127 0.16 
12 482 158 83k 129 992 128 52k 161 0.58 
TABLE Ill Change in Ejection Fraction (%) 
lmazodan lmazodan lmazodan 
Placebo (2 mg BID) (5 mg BID) (10 mg BID) 
0.25 f 6.9 -0.09 + 6.7 
TABLE IV Change in Average 24-Hour Heart Rate 
lmazodan lmazodan lmazodan p 
Week Placebo (2 mg BID) (5 mg BID) (10 mg BID) Value 
1 1.5 f 4.7 0.5 + 6.0 4.8 f 7.4 4.8 f 6.0 <0.005 
4 -0.5 k 6.6 2.0 f 9.0 4.3 -+ 8.8 6.4 +- 7.0 0.005 
10 -2.2 f 6.6 -0.2 ir 6.7 4.3 -c 10.6 6.0 2 10.3 10.005 
mia on the week 1 Holter. These were distributed even- 
ly through the 4 treatment groups. 
Safety: Patient withdrawals during the double-blind 
phase are listed in Table VI. There was a tendency for 
greater withdrawal from the placebo group for lack of 
efficacy than from the imazodan treatment groups. No 
adverse effects related to imazodan were reported. In- 
vestigators reported 7 patients with severe adverse ef- 
fects requiring withdrawal from the study: These in- 
cluded stomach irritation, resuscitated sudden death, 
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170 ?Z 313 106 f 185 
188 + 327 143 z!Y 179 
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lmazodan P 
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140 f 228 0.52 
109 f 158 0.49 
98 -t- 114 0.33 
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TABLE VI Reasons for Patient Withdrawal During 
Double-Blind Treatment and Numbers of Patients Completing 
the 12.Week Period 
lmazodan lmazodan lmazodan 
Placebo (2 mg BID) (5 mg BID) (10 mg BID) 
Death 0 0 4 3 
Adverse experience 2 0 3 2 
Lack of efficacy 3 1 0 0 
Concurrent illness 2 2 0 1 
Other withdrawal 6 2 6 4 
Completed week 12 32 30 26 22 
lightheadedness and headache, nausea, anorexia and 
weakness, postural dizziness and hypotension, worsen- 
ing CHF and ventricular arrhythmias. 
There were 13 patients with ventricular arrhythmias 
reported as adverse events by the investigators. Of 
these, 6 were receiving placebo, 1 was receiving imazo- 
dan 2 mg, 4 imazodan 5 mg and 2 imazodan 10 mg 
twice daily. 
By intent-to-treat analysis the mortality in the pla- 
cebo group was 7% (3 of 44) and in the imazodan 
groups 8% (8 of 103) (p = not significant). During the 
double-blind phase of the study there were 7 deaths, 5 
of them sudden. Four deaths occurred in the imazodan 
5 mg and 3 in the imazodan 10 mg groups. There were 
4 additional deaths during the 12-week period in pa- 
tients who were withdrawn from the double-blind 
phase. Three were originally in the placebo group and 
at the time of death 1 of these was taking imazodan 5 
mg and another 15 mg twice daily. One was initially in 
the imazodan IO-mg group, but was withdrawn while 
hospitalized for CHF and died 11 days later. Patients 
who died had lower ejection fraction (14 vs 23%, p 
<0.02), lower baseline exercise times (379 vs 512 sec- 
onds, p <0.02), and were less likely to be taking an 
angiotensin-converting enzyme inhibitor (14 vs 57%, p 
<0.03). 
DISCUSSION 
This study examined the efficacy and safety of a 
new type III phosphodiesterase inhibitor over a range of 
doses. During the 3 months of follow-up, exercise per- 
formance and ejection fraction did not significantly im- 
prove when compared with the effect of the placebo. 
The drug appeared to be well tolerated. Frequency of 
ventricular ectopy did not increase, although there was 
the increase in heart rate seen in the patients taking the 
larger doses of imazodan. The cause of this chrono- 
tropic response has not been previously described and 
warrants further investigation. 
Previous studies with imazodan ((X-914),* its ana- 
log CI-9309 and other phosphodiesterase inhibitors in- 
dicate that intravenous,and oral therapy results in an 
increase in cardiac output and a reduction in peripheral 
vascular resistance. Although most studies suggest that 
these drugs have a positive inotropic action, it is difli- 
cult, in humans, to separate the effect on contractility 
from the direct vasodilatation. Patients treated with CI- 
9309 were observed to have an increase in frequency of 
ventricular ectopy which was not found in this study. 
Other phosphodiesterase inhibitors have been evalu- 
ated for the treatment of chronic CHF. Amrinone4 and 
milrinone,5 both bipyridine derivatives, have significant 
inotropic and vasodilator effects in the acute setting. 
The effects of long-term amrinone therapy on exercise 
performance have been disappointing. Massie et ali2 
compared amrinone with placebo in 99 patients with 
chronic CHF and found no difference in exercise ability 
over a 12-week period. A multicenter placebo-con- 
trolled comparison of milrinone with digoxinr3 found an 
improvement in exercise performance in patients given 
either milrinone or digoxin when compared with place- 
bo, but no additional benefit to the combination of mil- 
rinone and digoxin. 
Enoximone6 and piroximone,7 like imazodan, are 
imidazol derivatives with acute hemodynamic effects 
similar to amrinone and milrinone. Whereas there have 
been numerous acute and chronic studies of enoxi- 
mone20 in patients with heart failure, few have been 
controlled. Uretsky et a1,16 in a study of 102 patients 
with chronic CHF, found no improvement in exercise 
capacity or symptoms compared with placebo. 
The design of this study would have permitted an 
analysis of mortality over 12 weeks although the power 
was not calculated for studying survival. However, pa- 
tients who discontinued the double-blind study early 
were allowed to begin the open-label phase immediate- 
ly. This resulted in the administration of imazodan, be- 
fore 84 days, to some patients randomized to placebo. 
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By intent-to-treat analysis for the 84 days, there was no 
significant difference in mortality between the placebo 
group (7%) and those treated with imazodan (8%). 
The fact that all the deaths that occurred during the 
double-blind phase were in patients taking large doses 
of imazodan is disturbing. The effect of phosphodiester- 
ase inhibitors on survival has not been studied in a rig- 
orous manner. Most of the initial hemodynamic studies 
were conducted in patients with severe heart failure in 
whom the expected mortality was high. In the few pla- 
cebo-controlled studies,12,13*16 as in this study, there has 
been a disturbing and consistent trend toward increased 
mortality in the treatment group. Colucci21 reviewed 
571 patients enrolled in 3 placebo-controlled studies of 
milrinone and concluded that there was no evidence for 
an adverse effect of that drug on mortality. In the larg- 
est of these studies, however, there was a trend (p = 
0.08) toward reduced survival in the milrinone-treated 
group. The investigators attributed this to a baseline 
imbalance in ejection fraction which suggested that 
milrinone was given to a sicker population. After post 
hoc adjustment of this covariant, the trend toward in- 
creased mortality was no longer present. Recently, a 
mortality study of milrinone in patients with class III 
and IV heart failure was prematurely terminated be- 
cause of increased mortality in the milrinoneztreated 
group (Schwartz R, personal communication, Sterling 
Winthrop, Inc.). Uretsky et all6 found a higher mortal- 
ity in enoximone-treated patients than in a placebo- 
treated group. This increase in mortality was signifi- 
cant when the study was analyzed by double-blind (p 
<0.0.5) or intention-to-treat (p <0.05) analyses. In our 
study, the increased mortality rate was observed in the 
large dose ranges, suggesting a dose effect. 
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